Company Overview
About NextPoint Therapeutics
NextPoint Therapeutics is a clinical-stage biotechnology company developing precision immuno-oncology therapeutics that target the HHLA2 (B7-H7) immune checkpoint pathway. HHLA2 is a novel checkpoint ligand that suppresses anti-tumor T cell and NK cell activity in many solid tumors independently of PD-L1, providing a rationale for combination with existing checkpoint inhibitors or as a monotherapy in PD-L1-resistant tumors.
Business Model & Competitive Advantage
The company has two clinical programs in Phase 1 trials. NPX267 is in a Phase 1 dose escalation and expansion study in HHLA2-expressing solid tumors including non-small cell lung, renal cell, colorectal, bile duct, pancreatic, and prostate cancers. NPX887, a fully human monoclonal antibody against HHLA2, received FDA IND clearance in December 2023, with the first patient dosed in its Phase 1a/b trial in February 2024. NextPoint raised $80 million in a Series B co-led by Leaps by Bayer and Sanofi Ventures in January 2023, followed by a $42.5 million Series B extension led by Catalio Capital Management in February 2024, bringing total funding to approximately $122.5 million.
Competitive Landscape 2025–2026
NextPoint Therapeutics competes in the emerging HHLA2 targeting space alongside Compugen and other companies exploring B7 family checkpoint inhibitors. Its competitive moat lies in having two clinical-stage assets targeting HHLA2 and deep scientific expertise in this specific pathway, backed by strategic investors with immunotherapy expertise.
Key Differentiators
Strong Challenger
NextPoint Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Florence Healthcare
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to stre
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare NextPoint Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from NextPoint Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim NextPoint Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention NextPoint Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →